| __timestamp | Apellis Pharmaceuticals, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 2652041 |
| Thursday, January 1, 2015 | 6356782 | 2361587 |
| Friday, January 1, 2016 | 4303743 | 4472869 |
| Sunday, January 1, 2017 | 10463151 | 5030957 |
| Monday, January 1, 2018 | 22639184 | 4988941 |
| Tuesday, January 1, 2019 | 67046483 | 5196412 |
| Wednesday, January 1, 2020 | 139401000 | 6652774 |
| Friday, January 1, 2021 | 176771000 | 18418247 |
| Saturday, January 1, 2022 | 277163000 | 24827066 |
| Sunday, January 1, 2023 | 500815000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Data in motion
In the competitive landscape of biotechnology, operational efficiency is paramount. Over the past decade, Apellis Pharmaceuticals, Inc. and Opthea Limited have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Apellis, with its aggressive expansion strategy, saw its SG&A costs skyrocket by over 17,000% from 2014 to 2023, peaking at approximately $500 million in 2023. In contrast, Opthea maintained a more conservative growth, with expenses increasing by around 1,500% over the same period, reaching nearly $42 million in 2023.
This divergence highlights Apellis's focus on rapid scaling, likely driven by its ambitious R&D and market penetration efforts. Meanwhile, Opthea's steady approach suggests a focus on sustainable growth. The absence of 2024 data for Apellis leaves room for speculation on its future strategy. As these companies continue to evolve, their SG&A trends offer valuable insights into their operational priorities and market positioning.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Opthea Limited
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Opthea Limited
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Opthea Limited
Operational Costs Compared: SG&A Analysis of Opthea Limited and PTC Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Opthea Limited vs Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Opthea Limited or Xencor, Inc.
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared